新药对分子遗传学异常的多发性骨髓瘤患者预后的影响

Prognostic effects of novel agents on cytogenetic abnormalities of multiple myeloma

多发性骨髓瘤（MM）是一种异质性疾病，常伴随多种分子遗传学异常，如lq21扩增，t（4；14）、17p缺失等。这些分子遗传学异常的出现常提示预后不良。随着沙利度胺、来那度胺及硼替佐米等新药的广泛使用，MM的生存得剑硅著提高。目前许多研究显示部分新药能克服或至少部分克服某些分子遗传学异常对预后的不良影响，但这些新药对分子遗传学异常的影响仍存在较大的争议。文章通过对近些年来新药对分子遗传学异常MM患者的预后影响作一综述，以期为临床治疗提供帮助。

Multiple myeloma （MM） is a heterogeneous disease with certain cytogenetic abnormalities [lq21 gains, t（4;14）, del 17p] associated with worse outcome. The extensive use Hf thalidomide, lenalidomide and bortezomib has dramatically improved the outcome for patients with MM and some cytogenetic abnormalities. It is also widely proved that hortezomib can partly overcome the harmful affects of t （4;14）. However, till now, there are many controversies about the effects of some novel agents worked on certain cytogenetic abnormalities. In this review, the effects of novel agents in cytogenetic abnormalities were summaried to provide new information on clinical treatment of this disease.